What is Cumberland Pharmaceuticals Price-to-Operating-Cash-Flow?
As of today (2024-04-25), Cumberland Pharmaceuticals's share price is $1.70.
Cumberland Pharmaceuticals's Cash Flow from Operations per share for the trailing twelve months (TTM) ended in Dec. 2023 was $0.42. Hence, Cumberland Pharmaceuticals's Price-to-Operating-Cash-Flow Ratio for today is 4.02.
The historical rank and industry rank for Cumberland Pharmaceuticals's Price-to-Operating-Cash-Flow or its related term are showing as below:
CPIX'
s Price-to-Operating-Cash-Flow Range Over the Past 10 Years
Min: 2.11 Med: 15.08 Max: 7200
Current: 4.02
During the past 13 years, Cumberland Pharmaceuticals's highest Price-to-Operating-Cash-Flow Ratio was 7200.00. The lowest was 2.11. And the median was 15.08.
Cumberland Pharmaceuticals's Cash Flow from Operations per share for the
three
months ended in Dec. 2023 was $0.07.
Its Cash Flow from Operations per share for the trailing twelve months (TTM) ended in Dec. 2023 was $0.42.
During the past 12 months, the average Operating Cash Flow per Share Growth Rate of Cumberland Pharmaceuticals was -26.60% per year.
During the past 3 years, the average Operating Cash Flow per Share Growth Rate was 6.10% per year.
During the past 5 years, the average Operating Cash Flow per Share Growth Rate was 22.90% per year.
During the past 13 years, Cumberland Pharmaceuticals's highest 3-Year average Operating Cash Flow per Share Growth Rate was 154.10% per year. The lowest was -68.70% per year. And the median was 4.60% per year.
Cumberland Pharmaceuticals Price-to-Operating-Cash-Flow Historical Data
The historical data trend for Cumberland Pharmaceuticals's Price-to-Operating-Cash-Flow can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Cumberland Pharmaceuticals Price-to-Operating-Cash-Flow Chart
|
Cumberland Pharmaceuticals Annual Data
|
|
Trend |
Dec14 |
Dec15 |
Dec16 |
Dec17 |
Dec18 |
Dec19 |
Dec20 |
Dec21 |
Dec22 |
Dec23 |
| Price-to-Operating-Cash-Flow |
|
Get a 7-Day Free Trial
|
|
|
26.01 |
8.26 |
10.99 |
3.88 |
4.21 |
|
Cumberland Pharmaceuticals Quarterly Data
|
|
Mar19 |
Jun19 |
Sep19 |
Dec19 |
Mar20 |
Jun20 |
Sep20 |
Dec20 |
Mar21 |
Jun21 |
Sep21 |
Dec21 |
Mar22 |
Jun22 |
Sep22 |
Dec22 |
Mar23 |
Jun23 |
Sep23 |
Dec23 |
| Price-to-Operating-Cash-Flow |
Get a 7-Day Free Trial
|
|
|
|
|
|
|
|
|
|
|
|
|
3.88 |
3.92 |
2.11 |
3.13 |
4.21 |
Competitive Comparison of Cumberland Pharmaceuticals's Price-to-Operating-Cash-Flow
For the Drug Manufacturers - Specialty & Generic subindustry, Cumberland Pharmaceuticals's Price-to-Operating-Cash-Flow, along with its competitors' market caps and Price-to-Operating-Cash-Flow data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Cumberland Pharmaceuticals's Price-to-Operating-Cash-Flow Distribution in the Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Cumberland Pharmaceuticals's Price-to-Operating-Cash-Flow distribution charts can be found below:
* The bar in red indicates where Cumberland Pharmaceuticals's Price-to-Operating-Cash-Flow falls into.
Cumberland Pharmaceuticals Price-to-Operating-Cash-Flow Calculation
Cumberland Pharmaceuticals's Price-to-Operating-Cash-Flow ratio for today is calculated as
| Price-to-Operating-Cash-Flow Ratio | = | Share Price | / | Cash Flow from Operations per share (TTM) |
| = | 1.70 | / | 0.423 |
| = | 4.02 |
Cumberland Pharmaceuticals's Share Price of today is $1.70.
Cumberland Pharmaceuticals's Cash Flow from Operations per share for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.42.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Note: Cash Flow from Operations per share is calculated as Cash Flow from Operations divided by Shares Outstanding (Diluted Average).
It can also be calculated from the numbers for the whole company:
Cumberland Pharmaceuticals (Cumberland Pharmaceuticals) Business Description
Traded in Other Exchanges
N/A
Address
1600 West End Avenue, Suite 1300, Nashville, TN, USA, 37203
Cumberland Pharmaceuticals Inc is a specialty pharmaceutical company focused on the acquisition, development, and commercialization of branded prescription pharmaceutical products. The company's primary target markets are hospital acute care, gastroenterology, rheumatology, and oncology. The company promotes its approved products through its hospital, field, and oncology sales divisions in the United States and establishes a network of international partners to register and provide medicines to patients in their countries. The company's revenue is derived from the product sales of FDA-approved pharmaceutical brands. Its brands include Acetadote, Caldolor, Kristalose, Omeclamox, RediTrex, Sancuso, Vaprisol and Vibativ.
Executives
| Todd M. Anthony |
officer: Vice Pres Organizational Dev |
1600 WEST END AVENUE, SUITE 1300, NASHVILLE TN 37203 |
| Chris T. Bitterman |
officer: Vice Pres Sales & Marketing |
1600 WEST END AVENUE, SUITE 1300, NASHVILLE TN 37203 |
| Joseph C Galante |
director |
111 TENTH AVENUE, SUITE 200, NASHVILLE TN 37203 |
| James Jones |
director |
2525 WEST END AVE., SUITE 950, NASHVILLE TN 37203 |
| Kenneth Krogulski |
director |
2525 WEST END AVENUE, SUITE 950, NASHVILLE TN 37203 |
| Caroline Young |
director |
2525 WEST END AVENUE, SUITE 950, NASHVILLE TN 37203 |
| Brown Martin S Jr |
director |
850 DIXIE HIGHWAY, LOUISVILLE KY 40210 |
| A J Kazimi |
director, 10 percent owner, officer: Chairman and CEO |
1207 17TH AVENUE SUITE 103, NASHVILLE TN 37212 |
| Martin E Cearnal |
director |
31 UPPER MOUNTAIN AVENUE, APARTMENT 2, MONTCLAIR NJ 07042 |
| John M. Hamm |
officer: Chief Financial Officer |
2525 WEST END AVENUE, SUITE 950, NASHVILLE TN 37203 |
| Gordon R Bernard |
officer: Senior Vice President |
2525 WEST END AVENUE, SUITE 950, NASHVILLE TN 37203 |
| Joey A Jacobs |
director |
830 CRESCENT CENTER DRIVE, SUITE 610, FRANKLIN TN 37067 |
| Michael Bonner |
officer: Chief Financial Officer |
2525 WEST END AVENUE, SUITE 950, NASHVILLE TN 37203 |
| Jonathan Griggs |
director |
2525 WEST END AVENUE, SUITE 950, NASHVILLE TN 37203 |
| Thomas R Lawrence |
director |
1880 ELLINGTON WAY, AUBURN AL 36830 |
Cumberland Pharmaceuticals (Cumberland Pharmaceuticals) Headlines
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
CPIX has been successfully added to your